Clinical trial · Interventional
Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer
NCT06144762CI-TRIAL-00085899PANC-O-MICSrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Specifically, in this project, the objective will be developped a model to capture imaging-based tumor heterogeneity with multiscale radiomics approach by obtaining the mirror tumor image at in vivo MRI, ex vivo MRI at histology. This imaging model giving a perfect virtual histology tumor representation will be secondary implemented on routine in vivo clinical MRI for early cancer detection and treatment monitoring. Successful completion of this proposal will lead to a comprehensive non invasive characterisation of pancreatic cancer and will be a game changer in patient management.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biological/Vaccine: Blood sample and tissue sample | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Blood sample and tissue sample
- description
- Blood sample and tissue sample
- interventionNames
- Biological: Biological/Vaccine: Blood sample and tissue sample
Primary outcomes (1)
- measure
- the integration of in vivo and ex vivo MRI with histology and molecular caracteristic in order to increase the pancreatic cancer detection and therapeutic response monitoring
- timeFrame
- The day of the surgery
- description
- The diagnostic performance of the radiomic and multiomic algorithm in pancreatic cancer detection and therapeutic response monitoring.
Secondary outcomes (4)
- measure
- the imaging phenotype of tumor heterogeneity with a multi-scale radiomic approach by obtaining the image mirror tumor at the in vivo scale
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient aged \>18 2. * Pathologically proven pancreatic cancer which can beneficiate of upfront surgery or delayed surgery followed by neoadjuvant chemotherapy. * Negative pregnancy test for women of childbearing potential * Patients affiliated to a social protection system * Written informed consent signed before project onset. Exclusion Criteria: * presence of metastases, * Patient who will not have surgery * Pregnant or breastfeeding women * Mental or psychological state, physical or legal incapacity preventing participation in the project.
References
Publications (18)
- BACKGROUNDNougaret S, Lakhman Y, Gourgou S, Kubik-Huch R, Derchi L, Sala E, Forstner R; European Society of Radiology (ESR) and the European Society of Urogenital Radiology (ESUR). MRI in female pelvis: an ESUR/ESR survey. Insights Imaging. 2022 Mar 28;13(1):60. doi: 10.1186/s13244-021-01152-w. PMID 35347481
- BACKGROUNDSoyer P, Revel MP, Dohan A, Vernhet-Kovacsik H, Nougaret S, Hoeffel C. Gender diversity in authorship in Diagnostic & Interventional Imaging: Where are we now? Diagn Interv Imaging. 2022 May;103(5):237-239. doi: 10.1016/j.diii.2022.02.001. Epub 2022 Feb 17. No abstract available. PMID 35183485
- BACKGROUNDTardieu M, Lakhman Y, Khellaf L, Cardoso M, Sgarbura O, Colombo PE, Crispin-Ortuzar M, Sala E, Goze-Bac C, Nougaret S. Assessing Histology Structures by Ex Vivo MR Microscopy and Exploring the Link Between MRM-Derived Radiomic Features and Histopathology in Ovarian Cancer. Front Oncol. 2022 Jan 19;11:771848. doi: 10.3389/fonc.2021.771848. eCollection 2021. PMID 35127479
- BACKGROUNDSadowski EA, Thomassin-Naggara I, Rockall A, Maturen KE, Forstner R, Jha P, Nougaret S, Siegelman ES, Reinhold C. O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee. Radiology. 2022 Apr;303(1):35-47. doi: 10.1148/radiol.204371. Epub 2022 Jan 18. PMID 35040672
- BACKGROUNDShinagare AB, Sadowski EA, Park H, Brook OR, Forstner R, Wallace SK, Horowitz JM, Horowitz N, Javitt M, Jha P, Kido A, Lakhman Y, Lee SI, Manganaro L, Maturen KE, Nougaret S, Poder L, Rauch GM, Reinhold C, Sala E, Thomassin-Naggara I, Vargas HA, Venkatesan A, Nikolic O, Rockall AG. Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR Uterine and Ovarian Cancer Disease-Focused Panel and the ESUR Female Pelvic Imaging Working Group. Eur Radiol. 2022 May;32(5):3220-3235. doi: 10.1007/s00330-021-08390-y. Epub 2021 Nov 30. PMID 34846566
- BACKGROUNDTibermacine H, Rouanet P, Sbarra M, Forghani R, Reinhold C, Nougaret S; GRECCAR Study Group. Radiomics modelling in rectal cancer to predict disease-free survival: evaluation of different approaches. Br J Surg. 2021 Oct 23;108(10):1243-1250. doi: 10.1093/bjs/znab191.